

Fasenra® (benralizumab) (Subcutaneous)

Document Number: IC-P0347

Last Review Date: 07/01/2026

Date of Origin: 12/12/2017

Dates Reviewed: 12/2017, 03/2018, 06/2018, 10/2018, 11/2019, 01/2020, 10/2020, 03/2021, 08/2021, 10/2022, 10/2023, 05/2024, 10/2024, 01/2025, 03/2026, 07/2026

I. Length of Authorization

- Initial: Prior authorization validity will be provided initially for 12 months (365 days).
- Renewal: Prior authorization validity may be renewed every 12 months (365 days) thereafter.

II. Dosing Limits

Max Units (per dose and over time) [HCPCS Unit]:

- **Severe Eosinophilic Asthma:**
 - Load: 30 billable units every 28 days for 3 doses
 - Maintenance: 30 billable units every 56 days
- **Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES):**
 - 30 billable units every 28 days

III. Initial Approval Criteria

Target Agent(s) will be approved when ALL of the following are met:

1. ONE of the following:

A. The requested agent is eligible for continuation of therapy AND ONE of the following:

Agents Eligible for Continuation of Therapy
All target agents are eligible for continuation of therapy

1. The member has been treated with the requested agent (starting on samples is not approvable) within the past 90 days; **OR**
2. The prescriber states the member has been treated with the requested agent (starting on samples is not approvable) within the past 90 days AND is at risk if therapy is changed; **OR**

B. BOTH of the following:

1. ONE of the following:

A. The member has a diagnosis of severe eosinophilic asthma and BOTH of the following:

1. The member's diagnosis has been confirmed by ONE of the following:
 - A. Baseline (prior to therapy with the requested agent) blood eosinophil count of 150 cells/microliter or higher; **OR**
 - B. Fraction of exhaled nitric oxide (FeNO) of 20 parts per billion or higher while on high-dose inhaled corticosteroids or daily oral corticosteroids; **OR**
 - C. Sputum eosinophils 2% or higher while on high-dose inhaled corticosteroids or daily oral corticosteroids; **OR**
 - D. The member is dependent on systemic corticosteroids;
AND
2. ONE of the following:
 - A. The member has a history of uncontrolled asthma while on asthma control therapy (e.g., inhaled corticosteroid [ICS]/long-acting beta-2 agonist [LABA] combination therapy) as demonstrated by ONE of the following:
 1. Two or more severe asthma exacerbations (i.e., required treatment with a systemic corticosteroid [steroid burst]) within the past 12 months; **OR**
 2. One or more serious asthma exacerbation(s) (i.e., required hospitalization, mechanical ventilation, or visit to the emergency room or urgent care) within the past 12 months; **OR**
 3. Controlled asthma that worsens when the doses of inhaled and/or systemic corticosteroids are tapered; **OR**
 4. Baseline (prior to therapy with the requested agent) Forced Expiratory Volume (FEV1) that is less than 80% of predicted; **OR**
 - B. The member's medication history (excluding sample use) indicates use of a biologic immunomodulator agent that is FDA labeled or supported in compendia for the treatment of asthma within the past 12 months; **OR**
- B. The member has a diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) and ALL of the following:
 1. The member has ONE of the following:
 - A. Baseline (prior to therapy for the requested indication) blood eosinophilia greater than or equal to 1000 cells/microliter; **OR**

- B. Baseline (prior to therapy for the requested indication) blood eosinophil level greater than or equal to 10% eosinophils on white blood cell differential count; **AND**
- 2. The member has a history or presence of asthma; **AND**
- 3. The member does NOT have severe disease with organ- or life-threatening manifestations (e.g., alveolar hemorrhage, glomerulonephritis, central nervous system vasculitis, mononeuritis multiplex, cardiac involvement, mesenteric ischemia, limb/digit ischemia); **AND**
- 4. ONE of the following:
 - A. BOTH of the following:
 - 1. The member is currently treated within the past 90 days with oral corticosteroid (OCS) therapy for at least 4 weeks; **AND**
 - 2. The member will be using oral corticosteroid (OCS) therapy in combination with the requested agent; **OR**
 - B. The member has an intolerance or hypersensitivity to ONE oral corticosteroid (OCS) used in the treatment of EGPA; **OR**
 - C. The member has an FDA labeled contraindication to ALL oral corticosteroids; **AND**
- 5. The member will be using the requested agent for ONE of the following:
 - A. Treatment of relapsing or refractory disease; **OR**
 - B. Treatment for maintenance of disease remission; **OR**
- C. The member has a diagnosis of hypereosinophilic syndrome (HES) and ALL of the following:
 - 1. The member has a baseline (prior to therapy with the requested agent) blood eosinophil count of 1000 cells/microliter or greater; **AND**
 - 2. There has been evaluation of hypereosinophilia-related organ involvement (e.g., heart, skin, lungs, gastrointestinal tract, nervous system); **AND**
 - 3. The member does NOT have an identifiable non-hematologic secondary (reactive) cause of HES (e.g., infection, allergy/atopy, autoimmune disease, drug reaction, metabolic condition, solid tumor/lymphoma); **AND**
 - 4. The member does NOT have FIP1L1-PDGFR α -positive disease; **AND**

5. The member has ONE of the following:
 - A. History of at least 2 HES flares (i.e., worsening of clinical symptoms and/or blood eosinophil counts requiring an escalation in therapy) within the past 12 months; **OR**
 - B. Active signs or symptoms of HES flare; **AND**
6. The member has ONE of the following:
 - A. Tried and had an inadequate response to ONE of the following used in the treatment of HES:
 1. Oral corticosteroid (OCS); **OR**
 2. Hydroxyurea; **OR**
 3. Interferon-alfa; **OR**
 4. Immunosuppressive agent (e.g., cyclosporine, methotrexate); **OR**
 - B. Become corticosteroid-dependent for the treatment of HES; **OR**
 - C. An intolerance or hypersensitivity to ONE oral corticosteroid, hydroxyurea, interferon-alfa, or immunosuppressive agent (e.g., cyclosporine, methotrexate) used in the treatment of HES; **OR**
 - D. An FDA labeled contraindication to hydroxyurea, interferon-alfa, and ALL oral corticosteroids and immunosuppressives (e.g., cyclosporine, methotrexate) used in the treatment of HES; **AND**
7. The member will continue existing HES therapy (e.g., OCS, hydroxyurea, interferon-alfa, cyclosporine, methotrexate) in combination with the requested agent; **OR**
- D. The member has another FDA labeled indication for the requested agent and route of administration; **AND**
2. If the member has an FDA labeled indication, then ONE of the following:
 - A. The member's age is within FDA labeling for the requested indication for the requested agent; **OR**
 - B. There is support for using the requested agent for the member's age for the requested indication; **OR**
- C. The member has an indication that is supported in compendia for the requested agent and route of administration; **AND**
2. If the member has a diagnosis of severe eosinophilic asthma, then ALL of the following:
 - A. ONE of the following:
 1. The member is NOT currently treated with a biologic immunomodulator agent that is FDA labeled or supported in compendia for the treatment of asthma

- (including the requested agent) AND is currently treated with a maximally tolerated inhaled corticosteroid for at least 3 months AND has been adherent for 90 days within the past 120 days; **OR**
2. The member is currently treated with a biologic immunomodulator agent that is FDA labeled or supported in compendia for the treatment of asthma (including the requested agent) AND ONE of the following:
 - A. The member is currently treated with an inhaled corticosteroid for at least 3 months that is adequately dosed to control symptoms AND has been adherent for 90 days within the past 120 days; **OR**
 - B. The member is currently treated with a maximally tolerated inhaled corticosteroid for at least 3 months AND has been adherent for 90 days within the past 120 days; **OR**
 3. The member has an intolerance or hypersensitivity to ONE inhaled corticosteroid; **OR**
 4. The member has an FDA labeled contraindication to ALL inhaled corticosteroids; **AND**
- B. ONE of the following:
1. The member is currently treated for at least 3 months AND has been adherent for 90 days within the past 120 days with ONE of the following:
 - A. A long-acting beta-2 agonist (LABA); **OR**
 - B. A long-acting muscarinic antagonist (LAMA); **OR**
 - C. A leukotriene receptor antagonist (LTRA); **OR**
 - D. Theophylline; **OR**
 2. The member has an intolerance or hypersensitivity to ONE long-acting beta-2 agonist (LABA), long-acting muscarinic antagonist (LAMA), leukotriene receptor antagonist (LTRA), or theophylline; **OR**
 3. The member has an FDA labeled contraindication to ALL long-acting beta-2 agonists (LABA) AND long-acting muscarinic antagonists (LAMA); **AND**
- C. The member will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent; **AND**
3. The prescriber is a specialist in the area of the member's diagnosis (e.g., asthma: allergist, immunologist, pulmonologist; EGPA or HES: allergist, immunologist, pulmonologist, rheumatologist) or the prescriber has consulted with a specialist in the area of the member's diagnosis; **AND**
 4. ONE of the following (Please refer to "Agents NOT to be used Concomitantly" table):
 - A. The member will NOT be using the requested agent in combination with another immunomodulatory agent (e.g., TNF inhibitors, JAK inhibitors, IL-4 inhibitors); **OR**
 - B. The member will be using the requested agent in combination with another immunomodulatory agent AND BOTH of the following:

1. The prescribing information for the requested agent does NOT limit the use with another immunomodulatory agent; **AND**
2. There is support for the use of combination therapy (submitted copy of clinical trials, phase III studies, or guidelines required); **AND**
5. The member does NOT have any FDA labeled contraindications to the requested agent

Compendia Allowed: AHFS, DrugDex 1 or 2a level of evidence, or NCCN 1 or 2a recommended use

IV. Renewal Criteria

Target Agent(s) will be approved when ALL of the following are met:

1. The member has been previously approved for the requested agent through the plan's Prior Authorization process (Note: members not previously approved for the requested agent will require initial evaluation review); **AND**
2. The member has had clinical benefit with the requested agent; **AND**
3. If the member has a diagnosis of severe eosinophilic asthma, then the member is currently treated within the past 90 days and is compliant with asthma control therapy (e.g., inhaled corticosteroids [ICS], ICS/long-acting beta-2 agonist [ICS/LABA], leukotriene receptor antagonist [LTRA], long-acting muscarinic antagonist [LAMA], theophylline); **AND**
4. The prescriber is a specialist in the area of the member's diagnosis (e.g., asthma: allergist, immunologist, pulmonologist; EGPA or HES: allergist, immunologist, pulmonologist, rheumatologist) or the prescriber has consulted with a specialist in the area of the member's diagnosis; **AND**
5. ONE of the following (Please refer to "Agents NOT to be used Concomitantly" table):
 - A. The member will NOT be using the requested agent in combination with another immunomodulatory agent (e.g., TNF inhibitors, JAK inhibitors, IL-4 inhibitors); **OR**
 - B. The member will be using the requested agent in combination with another immunomodulatory agent AND BOTH of the following:
 1. The prescribing information for the requested agent does NOT limit the use with another immunomodulatory agent; **AND**
 2. There is support for the use of combination therapy (submitted copy of clinical trials, phase III studies, or guidelines required); **AND**
6. The member does NOT have any FDA labeled contraindications to the requested agent

Contraindicated as Concomitant Therapy
Agents NOT to be used Concomitantly Abrilada (adalimumab-afzb) Actemra (tocilizumab) Adalimumab

Contraindicated as Concomitant Therapy

Adbry (tralokinumab-ldrm)
Amjevita (adalimumab-atto)
Anzupgo (delgocitinib)
Arcalyst (rilonacept)
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
Benlysta (belimumab)
Bimzelx (bimekizumab-bkzx)
Cibinqo (abrocitinib)
Cimzia (certolizumab)
Cinqair (reslizumab)
Cosentyx (secukinumab)
Cyltezo (adalimumab-adbm)
Dupixent (dupilumab)
Ebglyss (lebrikizumab-lbkz)
Enbrel (etanercept)
Entyvio (vedolizumab)
Exdensur (depemokimab-ulaa)
Fasenra (benralizumab)
Hadlima (adalimumab-bwwd)
Hulio (adalimumab-fkjp)
Humira (adalimumab)
Hyrimoz (adalimumab-adaz)
Icotyde (icotrokinra)
Idacio (adalimumab-aacf)
Ilaris (canakinumab)
Ilumya (tildrakizumab-asmn)
Imuldosa (ustekinumab-srlf)
Inflectra (infliximab-dyyb)
Infliximab
Kevzara (sarilumab)
Kineret (anakinra)
Leqselvi (deuruxolitinib)
Litfulo (ritlecitinib)
Nemluvio (nemolizumab-ilto)
Nucala (mepolizumab)
Olumiant (baricitinib)
Omlyclo (omalizumab-igec)
OmvoH (mirikizumab-mrkz)
Opzelura (ruxolitinib)
Orencia (abatacept)
Otezla (apremilast)
Otezla XR (apremilast extended-release)
Otulfi (ustekinumab-aaaz)

Contraindicated as Concomitant Therapy

Pyzchiva (ustekinumab-ttwe)
Remicade (infliximab)
Renflexis (infliximab-abda)
Rhapsido (remibrutinib)
Riabni (rituximab-arrx)
Rinvoq (upadacitinib)
Rituxan (rituximab)
Rituxan Hycela (rituximab/hyaluronidase human)
Ruxience (rituximab-pvvr)
Saphnelo (anifrolumab-fnia)
Selarsdi (ustekinumab-aekn)
Siliq (brodalumab)
Simlandi (adalimumab-ryvk)
Simponi (golimumab)
Simponi ARIA (golimumab)
Skyrizi (risankizumab-rzaa)
Sotyktu (deucravacitinib)
Spevigo (spesolimab-sbzo) subcutaneous injection
Starjemza (ustekinumab-hmny)
Stelara (ustekinumab)
Steqeyma (ustekinumab-stba)
Taltz (ixekizumab)
Tezspire (tezepelumab-ekko)
Tofacitinib
Tofidence (tocilizumab-bavi)
Tremfya (guselkumab)
Truxima (rituximab-abbs)
Tyenne (tocilizumab-aazg)
Tyruko (natalizumab-sztn)
Tysabri (natalizumab)
Ustekinumab
Velsipity (etrasimod)
Wezlana (ustekinumab-auub)
Xeljanz (tofacitinib)
Xeljanz XR (tofacitinib extended release)
Xolair (omalizumab)
Yesintek (ustekinumab-kfce)
Yuflyma (adalimumab-aaty)
Yusimry (adalimumab-aqvh)
Zeposia (ozanimod)
Zymfentra (infliximab-dyyb)

V. Dosage/Administration

Indication	Dose
Severe Eosinophilic Asthma	<u>Adults and Pediatrics ≥ 12 Years of Age</u> Administer 30 mg (one injection) subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks thereafter. <u>Pediatrics 6 to 11 Years of Age (Body Weight Dosing)</u> • < 35 kg: 10 mg (one injection) administered subcutaneously every 4 weeks for the first 3 doses, and then every 8 weeks thereafter. • ≥ 35 kg: 30 mg (one injection) administered subcutaneously every 4 weeks for the first 3 doses, and then every 8 weeks thereafter.
Eosinophilic Granulomatosis with Polyangiitis (EGPA)	Administer 30 mg (one injection) subcutaneously every 4 weeks
Hypereosinophilic Syndrome (HES)	Administer 30 mg (one injection) subcutaneously every 4 weeks

VI. Billing Code/Availability Information

HCPCS Code:

- J0517 – Injection, benralizumab, 1 mg; 1 billable unit = 1 mg

NDC(s):

- Fasenra 10 mg/0.5 mL single-dose prefilled syringe: 00310-1745-xx
- Fasenra 30 mg/mL single-dose prefilled syringe: 00310-1730-xx
- Fasenra 30 mg/mL single-dose autoinjector FASENRA PEN: 00310-1830-xx

VII. References

1. Fasenra prescribing information. AstraZeneca Pharmaceuticals LP. May 2026.
2. Chung KF, Wenzel SE, Brozek J, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *The European Respiratory Journal*. 2014;43(2):343-373. doi:10.1183/09031936.00202013
3. Louis R, Satia I, Ojanguren I, et al. European Respiratory Society guidelines for the diagnosis of asthma in adults. *European Respiratory Journal*. 2022;60(3):2101585. doi:10.1183/13993003.01585-2021
4. Global Initiative for Asthma (GINA). *Global Strategy for Asthma Management and Prevention (2025 Update)*. 2025. <https://www.ginasthma.org>
5. Watanabe R, Hashimoto M. Eosinophilic Granulomatosis with Polyangiitis: Latest Findings and Updated Treatment Recommendations. *Journal of Clinical Medicine*. 2023;12(18):5996. doi:10.3390/jcm12185996

6. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. *Arthritis & Rheumatology*. 2021;73(8):1366-1383. doi:10.1002/art.41773
7. Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. *Annals of the Rheumatic Diseases*. 2022;81(3):309-314. doi:10.1136/annrheumdis-2021-221794
8. Valent P, Klion AD, Roufosse F, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. *Allergy*. 2023;78(1):47-59. doi:10.1111/all.15544
9. Shomali W, Gotlib J. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. *Am J Hematol*. 2024;99(5):946-968. doi:10.1002/ajh.2635227287
10. Caminati M, Carpagnano LF, Alberti C, et al. Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach. *World Allergy Organ J*. 2024;17(8):100928. doi:10.1016/j.waojou.2024.100928.
11. Groh M, Rohmer J, Etienne N, et al. French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes. *Orphanet J Rare Dis*. 2023;18(1):100. doi:10.1186/s13023-023-02696-4
12. Wechsler M, Nair P, Terrier B, et al. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. *New England Journal of Medicine*. 2024;390(10):911-921. doi:10.1056/nejmoa2311155
13. Bourdin A, Brusselle G, Couillard S, et al. Phenotyping of severe asthma in the era of broad-acting anti-asthma biologics. *The Journal of Allergy and Clinical Immunology in Practice*. 2024;12(4):809-823. doi:10.1016/j.jaip.2024.01.023
14. Emmi G, Bettiol A, Gelain E, et al. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. *Nature Reviews Rheumatology*. 2023;19(6):378-393. doi:10.1038/s41584-023-00958-w
15. Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. *Annals of the Rheumatic Diseases*. 2023;83(1):30-47. doi:10.1136/ard-2022-223764
16. Nguyen L, Saha A, Kuykendall A, Zhang L. Clinical and therapeutic intervention of hypereosinophilia in the era of molecular diagnosis. *Cancers*. 2024;16(7):1383. doi:10.3390/cancers16071383.

Appendix A – Non-Quantitative Treatment Limitations (NQTL) Factor Checklist

Non-quantitative treatment limitations (NQTLs) refer to the methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided under a health plan. These may include things like utilization review or prior authorization. The utilization management NQTL applies comparably, and not more stringently, to mental health/substance use disorder

(MH/SUD) Medical Benefit Prescription Drugs and medical/surgical (M/S) Medical Benefit Prescription Drugs. The table below lists the factors that were considered in designing and applying prior authorization to this drug/drug group, and a summary of the conclusions that Prime's assessment led to for each.

Factor	Conclusion
Indication	Yes: Consider for PA
Safety and efficacy	No: PA not a priority
Potential for misuse/abuse	No: PA not a priority
Cost of drug	Yes: Consider for PA

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
D72.110	Idiopathic hypereosinophilic syndrome [IHES]
D72.111	Lymphocytic Variant Hypereosinophilic Syndrome [LHES]
D72.119	Hypereosinophilic syndrome [HES], unspecified
J45.50	Severe persistent asthma, uncomplicated
J82.81	Chronic eosinophilic pneumonia
J82.82	Acute eosinophilic pneumonia
J82.83	Eosinophilic asthma
J82.89	Other pulmonary eosinophilia, not elsewhere classified
M30.1	Polyarteritis with lung involvement [Churg-Strauss]

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents:

<https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC